相似文献
1
Drug compounding for veterinary patients.
AAPS J. 2005 Sep 22;7(2):E281-7. doi: 10.1208/aapsj070229.
2
Extemporaneous compounding in veterinary practice: a New Zealand perspective.
N Z Vet J. 2013 Nov;61(6):311-5. doi: 10.1080/00480169.2013.773853. Epub 2013 Apr 2.
3
FDA/CVM's Compliance Policy Guide on compounding of drugs.
J Am Vet Med Assoc. 1996 Dec 15;209(12):2025-9.
4
The Current Landscape of Veterinary Compounding in the Veterinary Setting.
Int J Pharm Compd. 2019 Sep-Oct;23(5):428-433.
5
Veterinary compounding in small animals: a clinical pharmacologist's perspective.
Vet Clin North Am Small Anim Pract. 2006 Sep;36(5):1129-73, viii. doi: 10.1016/j.cvsm.2006.07.003.
6
Compounding for animal patients: contemporary issues.
J Am Pharm Assoc (2003). 2004 May-Jun;44(3):375-84; quiz 384-6. doi: 10.1331/154434504323064011.
7
Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
J Am Pharm Assoc (Wash). 2002 Sep-Oct;42(5):789-98. doi: 10.1331/108658002764653568.
8
Food and drug regulatory issues.
Vet Clin North Am Small Anim Pract. 1993 Sep;23(5):991-1005. doi: 10.1016/s0195-5616(93)50131-6.
9
Problems associated with veterinary compounding in swine practice.
J Am Vet Med Assoc. 1994 Jul 15;205(2):279-83.
10
Potency and stability of compounded formulations of chlorambucil, melphalan and cyclophosphamide.
Vet Comp Oncol. 2017 Dec;15(4):1558-1563. doi: 10.1111/vco.12301. Epub 2017 Jan 25.
引用本文的文献
1
Clinical evaluation of a novel fixed-dose combination tablet (Sentorphil ForteGold) versus compounded powdered medications in dogs with myxomatous mitral valve disease: a randomized, double-blind study.
Front Vet Sci. 2025 Aug 12;12:1622383. doi: 10.3389/fvets.2025.1622383. eCollection 2025.
2
Assessment of absorption of transdermal ondansetron in normal research cats.
J Feline Med Surg. 2017 Dec;19(12):1245-1248. doi: 10.1177/1098612X16688807. Epub 2017 Jan 23.
3
Veterinary Compounding: Regulation, Challenges, and Resources.
Pharmaceutics. 2017 Jan 10;9(1):5. doi: 10.3390/pharmaceutics9010005.
4
Drug exposure and clinical effect of transdermal mirtazapine in healthy young cats: a pilot study.
J Feline Med Surg. 2017 Oct;19(10):998-1006. doi: 10.1177/1098612X16667168. Epub 2016 Sep 1.
5
The use of fluoxetine by veterinarians in dogs and cats: a preliminary survey.
Vet Rec Open. 2016 Apr 8;3(1):e000146. doi: 10.1136/vetreco-2015-000146. eCollection 2016.
6
First feline case of otodectosis in the Republic of Korea and successful treatment with imidacloprid/moxidectin topical solution.
Korean J Parasitol. 2013 Feb;51(1):125-8. doi: 10.3347/kjp.2013.51.1.125. Epub 2013 Feb 18.
7
Compounding errors in 2 dogs receiving anticonvulsants.
Can Vet J. 2012 Apr;53(4):391-4.
8
Feline histoplasmosis: fluconazole therapy and identification of potential sources of Histoplasma species exposure.
J Feline Med Surg. 2012 Dec;14(12):841-8. doi: 10.1177/1098612X12452494. Epub 2012 Jun 26.
9
ISFM and AAFP consensus guidelines: long-term use of NSAIDs in cats.
J Feline Med Surg. 2010 Jul;12(7):521-38. doi: 10.1016/j.jfms.2010.05.004.
10
The role and education of the veterinary pharmacist.
Am J Pharm Educ. 2009 Feb 19;73(1):16. doi: 10.5688/aj730116.
本文引用的文献
1
Comparison of canine and human gastrointestinal physiology.
Pharm Res. 1986 Jun;3(3):123-31. doi: 10.1023/A:1016353705970.
2
Compounding for creatures: what works.
Int J Pharm Compd. 1999 May-Jun;3(3):182-5.
3
Evaluation of transdermal application of glipizide in a pluronic lecithin gel to healthy cats.
Am J Vet Res. 2005 Apr;66(4):581-8. doi: 10.2460/ajvr.2005.66.581.
4
Efficacy and safety of transdermal methimazole in the treatment of cats with hyperthyroidism.
J Vet Intern Med. 2004 Sep-Oct;18(5):651-5. doi: 10.1892/0891-6640(2004)18<651:easotm>2.0.co;2.
5
Systemic absorption of amitriptyline and buspirone after oral and transdermal administration to healthy cats.
J Vet Intern Med. 2004 Jan-Feb;18(1):43-6. doi: 10.1892/0891-6640(2004)18<43:saoaab>2.0.co;2.
6
Comparative bioavailability of fluoxetine after transdermal and oral administration to healthy cats.
Am J Vet Res. 2003 Aug;64(8):994-8. doi: 10.2460/ajvr.2003.64.994.
7
Comparison of serum dexamethasone concentrations in cats after oral or transdermal administration using pluronic lecithin organogel (PLO): a pilot study.
Vet Dermatol. 2003 Apr;14(2):83-9. doi: 10.1046/j.1365-3164.2003.00331.x.
8
Comparison of paste and suspension formulations of omeprazole in the healing of gastric ulcers in racehorses in active training.
J Am Vet Med Assoc. 2002 Oct 15;221(8):1139-43. doi: 10.2460/javma.2002.221.1139.
9
Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part II. Physiological considerations.
Adv Drug Deliv Rev. 2002 Oct 4;54(6):825-50. doi: 10.1016/s0169-409x(02)00071-6.
10
Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part I: biopharmaceutics and formulation considerations.
Adv Drug Deliv Rev. 2002 Oct 4;54(6):805-24. doi: 10.1016/s0169-409x(02)00070-4.
Zotero 插件